Evaluating Patient and Provider Preferences for a Once-Weekly Basal Insulin in Adults with Type 2 Diabetes
The global burden of disease of type 2 diabetes (T2D) is significant, and insulin currently plays a central role in T2D management. This study sought to assess the preferences of patients with T2D and healthcare providers (HCPs) involved in T2D care regarding a hypothetical once-weekly basal insulin...
Saved in:
Published in | Patient preference and adherence Vol. 18; pp. 411 - 424 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
New Zealand
Dove Medical Press Limited
01.01.2024
Dove Dove Medical Press |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The global burden of disease of type 2 diabetes (T2D) is significant, and insulin currently plays a central role in T2D management. This study sought to assess the preferences of patients with T2D and healthcare providers (HCPs) involved in T2D care regarding a hypothetical once-weekly basal insulin in comparison to current basal insulin options.
In a survey-based study in the United States that included a discrete choice experiment (DCE), patients with T2D (insulin naïve and current insulin users) and providers who treat individuals with T2D were asked to evaluate current basal insulins and identify attributes of importance regarding a hypothetical once-weekly basal insulin. A regression analysis was conducted to identify drivers of preference by relevant demographics, attitudes, and behaviors.
Most respondents (91% of patients with T2D and 89% of HCPs in the base case scenario) would choose a once-weekly basal insulin product over another type of basal insulin. Both patients with T2D and HCPs rated insulin type and delivery method to be attributes of highest importance in the discrete choice exercise. Current basal insulin users ("insulin experienced") reported higher levels of confidence that a once-weekly insulin would help them to achieve their desired blood sugar levels compared to their current basal insulin (5.7 vs 5.2 on a 7-point Likert scale). Most insulin-experienced respondents (88%) were likely to inquire about once-weekly basal insulin, and most HCPs (85%) indicated willingness to educate patients on management of their T2D using a once-weekly basal insulin.
Discussing preferences for T2D medication management is important for patients and HCPs to ensure treatments are offered for patients based on their preferences. This study showed that patient and provider preferences are similar towards a once-weekly basal insulin over current basal insulin preparations. |
---|---|
AbstractList | David Kerr,1 Jigar Ramesh Rajpura,2 Tarlan Namvar3 1Center for Health Systems Research, Sutter Health, Santa Barbara, CA, USA; 2Department of US Health Economic and Outcomes Research – Rare Disease Portfolio, Novo Nordisk Inc, Plainsboro, NJ, USA; 3Department of Evidence Synthesis and Value Assessment, Novo Nordisk Inc, Plainsboro, NJ, USACorrespondence: David Kerr, Diabetes Research and Digital Health Equity, Sutter Center for Health Systems Research, Santa Barbara, CA, USA, Tel +1 (805) 624-8688, Email david.kerr@sutterhealth.orgPurpose: The global burden of disease of type 2 diabetes (T2D) is significant, and insulin currently plays a central role in T2D management. This study sought to assess the preferences of patients with T2D and healthcare providers (HCPs) involved in T2D care regarding a hypothetical once-weekly basal insulin in comparison to current basal insulin options.Patients and Methods: In a survey-based study in the United States that included a discrete choice experiment (DCE), patients with T2D (insulin naïve and current insulin users) and providers who treat individuals with T2D were asked to evaluate current basal insulins and identify attributes of importance regarding a hypothetical once-weekly basal insulin. A regression analysis was conducted to identify drivers of preference by relevant demographics, attitudes, and behaviors.Results: Most respondents (91% of patients with T2D and 89% of HCPs in the base case scenario) would choose a once-weekly basal insulin product over another type of basal insulin. Both patients with T2D and HCPs rated insulin type and delivery method to be attributes of highest importance in the discrete choice exercise. Current basal insulin users (“insulin experienced”) reported higher levels of confidence that a once-weekly insulin would help them to achieve their desired blood sugar levels compared to their current basal insulin (5.7 vs 5.2 on a 7-point Likert scale). Most insulin-experienced respondents (88%) were likely to inquire about once-weekly basal insulin, and most HCPs (85%) indicated willingness to educate patients on management of their T2D using a once-weekly basal insulin.Conclusion: Discussing preferences for T2D medication management is important for patients and HCPs to ensure treatments are offered for patients based on their preferences. This study showed that patient and provider preferences are similar towards a once-weekly basal insulin over current basal insulin preparations.Plain Language Summary: Type 2 diabetes (T2D) is a medical condition where the body has difficulty managing insulin, a hormone used to control glucose, or sugar, that is broken down in the bloodstream. Many people with T2D have to take insulin to help their bodies manage their blood sugar effectively. We aimed to find out what people with T2D and healthcare providers (HCPs) think about a new type of basal insulin that only needs to be taken once a week, as compared to current basal insulins that are taken every day. We found that most people with T2D (91%) and HCPs (89%) would prefer a once-weekly insulin rather than another type of basal insulin. People with T2D currently taking insulin were also more confident that a once-weekly insulin could help control their blood sugar. Many people who are already using basal insulin (88%) said they would ask their HCP about a once-weekly insulin. HCPs said they were willing to educate patients about a once-weekly insulin (85%). This study shows that it is important for people with T2D and their HCPs to discuss what type of insulin is best for them, including the type of insulin and how often it is taken. Sharing preferences about medication options may be helpful in reducing the overall impact of the condition. Keywords: diabetes mellitus, type 2, insulin, long-acting, surveys and questionnaires, patient preference, provider preference Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use: https://youtu.be/yPQljy98UFw Type 2 diabetes (T2D) is a medical condition where the body has difficulty managing insulin, a hormone used to control glucose, or sugar, that is broken down in the bloodstream. Many people with T2D have to take insulin to help their bodies manage their blood sugar effectively. We aimed to find out what people with T2D and healthcare providers (HCPs) think about a new type of basal insulin that only needs to be taken once a week, as compared to current basal insulins that are taken every day. We found that most people with T2D (91%) and HCPs (89%) would prefer a once-weekly insulin rather than another type of basal insulin. People with T2D currently taking insulin were also more confident that a once-weekly insulin could help control their blood sugar. Many people who are already using basal insulin (88%) said they would ask their HCP about a once-weekly insulin. HCPs said they were willing to educate patients about a once-weekly insulin (85%). This study shows that it is important for people with T2D and their HCPs to discuss what type of insulin is best for them, including the type of insulin and how often it is taken. Sharing preferences about medication options may be helpful in reducing the overall impact of the condition. Purpose: The global burden of disease of type 2 diabetes (T2D) is significant, and insulin currently plays a central role in T2D management. This study sought to assess the preferences of patients with T2D and healthcare providers (HCPs) involved in T2D care regarding a hypothetical once-weekly basal insulin in comparison to current basal insulin options. Patients and Methods: In a survey-based study in the United States that included a discrete choice experiment (DCE), patients with T2D (insulin naive and current insulin users) and providers who treat individuals with T2D were asked to evaluate current basal insulins and identify attributes of importance regarding a hypothetical once-weekly basal insulin. A regression analysis was conducted to identify drivers of preference by relevant demographics, attitudes, and behaviors. Results: Most respondents (91% of patients with T2D and 89% of HCPs in the base case scenario) would choose a once-weekly basal insulin product over another type of basal insulin. Both patients with T2D and HCPs rated insulin type and delivery method to be attributes of highest importance in the discrete choice exercise. Current basal insulin users ("insulin experienced") reported higher levels of confidence that a once-weekly insulin would help them to achieve their desired blood sugar levels compared to their current basal insulin (5.7 vs 5.2 on a 7-point Likert scale). Most insulin-experienced respondents (88%) were likely to inquire about once-weekly basal insulin, and most HCPs (85%) indicated willingness to educate patients on management of their T2D using a once-weekly basal insulin. Conclusion: Discussing preferences for T2D medication management is important for patients and HCPs to ensure treatments are offered for patients based on their preferences. This study showed that patient and provider preferences are similar towards a once-weekly basal insulin over current basal insulin preparations. Plain Language Summary: Type 2 diabetes (T2D) is a medical condition where the body has difficulty managing insulin, a hormone used to control glucose, or sugar, that is broken down in the bloodstream. Many people with T2D have to take insulin to help their bodies manage their blood sugar effectively. We aimed to find out what people with T2D and healthcare providers (HCPs) think about a new type of basal insulin that only needs to be taken once a week, as compared to current basal insulins that are taken every day. We found that most people with T2D (91%) and HCPs (89%) would prefer a once-weekly insulin rather than another type of basal insulin. People with T2D currently taking insulin were also more confident that a once-weekly insulin could help control their blood sugar. Many people who are already using basal insulin (88%) said they would ask their HCP about a once-weekly insulin. HCPs said they were willing to educate patients about a once-weekly insulin (85%). This study shows that it is important for people with T2D and their HCPs to discuss what type of insulin is best for them, including the type of insulin and how often it is taken. Sharing preferences about medication options may be helpful in reducing the overall impact of the condition. Keywords: diabetes mellitus, type 2, insulin, long-acting, surveys and questionnaires, patient preference, provider preference The global burden of disease of type 2 diabetes (T2D) is significant, and insulin currently plays a central role in T2D management. This study sought to assess the preferences of patients with T2D and healthcare providers (HCPs) involved in T2D care regarding a hypothetical once-weekly basal insulin in comparison to current basal insulin options. In a survey-based study in the United States that included a discrete choice experiment (DCE), patients with T2D (insulin naïve and current insulin users) and providers who treat individuals with T2D were asked to evaluate current basal insulins and identify attributes of importance regarding a hypothetical once-weekly basal insulin. A regression analysis was conducted to identify drivers of preference by relevant demographics, attitudes, and behaviors. Most respondents (91% of patients with T2D and 89% of HCPs in the base case scenario) would choose a once-weekly basal insulin product over another type of basal insulin. Both patients with T2D and HCPs rated insulin type and delivery method to be attributes of highest importance in the discrete choice exercise. Current basal insulin users ("insulin experienced") reported higher levels of confidence that a once-weekly insulin would help them to achieve their desired blood sugar levels compared to their current basal insulin (5.7 vs 5.2 on a 7-point Likert scale). Most insulin-experienced respondents (88%) were likely to inquire about once-weekly basal insulin, and most HCPs (85%) indicated willingness to educate patients on management of their T2D using a once-weekly basal insulin. Discussing preferences for T2D medication management is important for patients and HCPs to ensure treatments are offered for patients based on their preferences. This study showed that patient and provider preferences are similar towards a once-weekly basal insulin over current basal insulin preparations. PurposeThe global burden of disease of type 2 diabetes (T2D) is significant, and insulin currently plays a central role in T2D management. This study sought to assess the preferences of patients with T2D and healthcare providers (HCPs) involved in T2D care regarding a hypothetical once-weekly basal insulin in comparison to current basal insulin options.Patients and MethodsIn a survey-based study in the United States that included a discrete choice experiment (DCE), patients with T2D (insulin naïve and current insulin users) and providers who treat individuals with T2D were asked to evaluate current basal insulins and identify attributes of importance regarding a hypothetical once-weekly basal insulin. A regression analysis was conducted to identify drivers of preference by relevant demographics, attitudes, and behaviors.ResultsMost respondents (91% of patients with T2D and 89% of HCPs in the base case scenario) would choose a once-weekly basal insulin product over another type of basal insulin. Both patients with T2D and HCPs rated insulin type and delivery method to be attributes of highest importance in the discrete choice exercise. Current basal insulin users ("insulin experienced") reported higher levels of confidence that a once-weekly insulin would help them to achieve their desired blood sugar levels compared to their current basal insulin (5.7 vs 5.2 on a 7-point Likert scale). Most insulin-experienced respondents (88%) were likely to inquire about once-weekly basal insulin, and most HCPs (85%) indicated willingness to educate patients on management of their T2D using a once-weekly basal insulin.ConclusionDiscussing preferences for T2D medication management is important for patients and HCPs to ensure treatments are offered for patients based on their preferences. This study showed that patient and provider preferences are similar towards a once-weekly basal insulin over current basal insulin preparations. Plain Language Summary: Type 2 diabetes (T2D) is a medical condition where the body has difficulty managing insulin, a hormone used to control glucose, or sugar, that is broken down in the bloodstream. Many people with T2D have to take insulin to help their bodies manage their blood sugar effectively. We aimed to find out what people with T2D and healthcare providers (HCPs) think about a new type of basal insulin that only needs to be taken once a week, as compared to current basal insulins that are taken every day. We found that most people with T2D (91%) and HCPs (89%) would prefer a once-weekly insulin rather than another type of basal insulin. People with T2D currently taking insulin were also more confident that a once-weekly insulin could help control their blood sugar. Many people who are already using basal insulin (88%) said they would ask their HCP about a once-weekly insulin. HCPs said they were willing to educate patients about a once-weekly insulin (85%). This study shows that it is important for people with T2D and their HCPs to discuss what type of insulin is best for them, including the type of insulin and how often it is taken. Sharing preferences about medication options may be helpful in reducing the overall impact of the condition. |
Audience | Academic |
Author | Kerr, David Rajpura, Jigar Ramesh Namvar, Tarlan |
Author_xml | – sequence: 1 givenname: David surname: Kerr fullname: Kerr, David organization: Center for Health Systems Research, Sutter Health, Santa Barbara, CA, USA – sequence: 2 givenname: Jigar Ramesh surname: Rajpura fullname: Rajpura, Jigar Ramesh organization: Department of US Health Economic and Outcomes Research - Rare Disease Portfolio, Novo Nordisk Inc, Plainsboro, NJ, USA – sequence: 3 givenname: Tarlan surname: Namvar fullname: Namvar, Tarlan organization: Department of Evidence Synthesis and Value Assessment, Novo Nordisk Inc, Plainsboro, NJ, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38375061$$D View this record in MEDLINE/PubMed |
BookMark | eNptkl2LEzEUhgdZcT_0ynsJCCJI6-RjMjNXS91dtbCwBVf0LmQyJ21qmtQk06X_3qytSwuSwDmcPHnJyXnPixPnHRTFa1yOCWb1x9lsMv7GKK9Y-aw4w7iuR03T_jw5yE-L8xiXZckpJ_hFcUobWlclx2fF8mYj7SCTcXM0ywFcQtL1aBb8xvQQcgIaAjgFEWkfkER3OR_9APhlt-iTjNKiqYuDNQ7lPekHmyJ6MGmB7rdrQARdG9lBgviyeK6ljfBqHy-K759v7q--jm7vvkyvJrcjVTGeRrpXrFFYNpqXvAOiqMKsqlmvQBKmeUOV7DgjUPNaatYBsA4ryjrJGeYtoxfFdKfbe7kU62BWMmyFl0b8LfgwFzIkoywIzTGWfdVRRSkjLWsrovu2LoFUrca8z1qXO6310K0gP8GlIO2R6PGJMwsx9xuBy6auMK-zwvu9QvC_B4hJrExUYK104IcoSEuaJo8O04y-3aFzmd9mnPZZUj3iYlI3WYvk5jM1_g-VVw8ro7I1tMn1owvvDi4sQNq0iN4OyXgXj8EPO1AFH2Oe-1OfuBSPVhPZamJvtUy_OfyaJ_aft-gfgjnPGg |
CitedBy_id | crossref_primary_10_3390_jcm13072113 |
Cites_doi | 10.2337/dc23-S009 10.1016/j.eprac.2022.04.006 10.1186/s12874-021-01209-w 10.1111/dom.13132 10.1136/bmjgh-2022-010942 10.2991/jegh.k.191028.001 10.1089/dia.2021.0164 10.2147/ppa.S101821 10.1136/postgradmedj-2019-137190 10.2337/dc21-2396 10.2337/dc22-0242 10.2147/ppa.S87935 10.1016/j.clinthera.2016.09.020 10.1016/S2213-8587(18)30051-2 10.1007/s13300-018-0421-5 10.3389/fendo.2019.00536 10.2147/ppa.S194598 10.1001/jama.2023.11313 10.2147/ppa.S114619 10.2337/dc17-1144 10.2337/diacare.28.11.2673 10.1177/1932296820973185 10.1111/dom.14871 10.2337/diaspect.29.3.166 10.2337/diaclin.22.3.147 10.3389/fpubh.2021.782964 10.1016/j.jval.2020.01.023 10.1136/bmjdrc-2020-001926 10.1177/1932296820963630 10.1080/03007995.2016.1253553 10.1016/j.amjmed.2008.03.022 10.1111/dom.14244 10.1016/s2213-8587(23)00093-1 10.1080/03007995.2022.2125259 10.2147/ppa.S204111 10.1001/jama.2023.2854 10.1185/03007995.2012.743458 10.1007/s13300-021-01097-9 10.1016/j.ijcard.2022.09.009 10.1016/j.dsx.2022.102615 10.1136/bmj.310.6972.83 |
ContentType | Journal Article |
Copyright | 2024 Kerr et al. COPYRIGHT 2024 Dove Medical Press Limited 2024 Kerr et al. 2024 Kerr et al. |
Copyright_xml | – notice: 2024 Kerr et al. – notice: COPYRIGHT 2024 Dove Medical Press Limited – notice: 2024 Kerr et al. 2024 Kerr et al. |
DBID | NPM AAYXX CITATION 7X8 5PM DOA |
DOI | 10.2147/PPA.S436540 |
DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Kerr et al |
EISSN | 1177-889X |
EndPage | 424 |
ExternalDocumentID | oai_doaj_org_article_f611ad5b3c334294952fd970e259f16d A786732683 10_2147_PPA_S436540 38375061 |
Genre | Journal Article |
GeographicLocations | United States |
GeographicLocations_xml | – name: United States |
GrantInformation_xml | – fundername: ; |
GroupedDBID | --- 0YH 123 29O 2WC 53G 5VS 7RV 8C1 8FI 8FJ 8G5 ABDBF ABUWG ACGFO ADBBV ADRAZ AENEX AFKRA AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BKEYQ BPHCQ BVXVI CCPQU DIK DWQXO E3Z EBD ESX F5P FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HYE IAO IHR IHW IPNFZ ITC KQ8 M2O M48 MK0 M~E NAPCQ NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC RIG RNS RPM TDBHL TR2 TUS UKHRP VDV AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c546t-fdc48c1a8f606be2c3c14574dcea24f683cab642e767af4bee4b1c34ba6416943 |
IEDL.DBID | RPM |
ISSN | 1177-889X |
IngestDate | Fri Oct 04 13:06:19 EDT 2024 Tue Sep 17 21:29:32 EDT 2024 Fri Aug 16 21:43:15 EDT 2024 Wed Mar 27 18:02:03 EDT 2024 Tue Mar 26 04:58:01 EDT 2024 Tue Aug 20 22:15:07 EDT 2024 Fri Aug 23 02:52:51 EDT 2024 Fri Oct 18 08:36:10 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | patient preference type 2 insulin diabetes mellitus provider preference surveys and questionnaires long-acting |
Language | English |
License | 2024 Kerr et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c546t-fdc48c1a8f606be2c3c14574dcea24f683cab642e767af4bee4b1c34ba6416943 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10875167/ |
PMID | 38375061 |
PQID | 2928854013 |
PQPubID | 23479 |
PageCount | 14 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_f611ad5b3c334294952fd970e259f16d pubmedcentral_primary_oai_pubmedcentral_nih_gov_10875167 proquest_miscellaneous_2928854013 gale_infotracmisc_A786732683 gale_infotracacademiconefile_A786732683 gale_healthsolutions_A786732683 crossref_primary_10_2147_PPA_S436540 pubmed_primary_38375061 |
PublicationCentury | 2000 |
PublicationDate | 2024-01-01 |
PublicationDateYYYYMMDD | 2024-01-01 |
PublicationDate_xml | – month: 01 year: 2024 text: 2024-01-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | New Zealand |
PublicationPlace_xml | – name: New Zealand |
PublicationTitle | Patient preference and adherence |
PublicationTitleAlternate | Patient Prefer Adherence |
PublicationYear | 2024 |
Publisher | Dove Medical Press Limited Dove Dove Medical Press |
Publisher_xml | – name: Dove Medical Press Limited – name: Dove – name: Dove Medical Press |
References | Robinson (ref18) 2021; 23 King (ref23) 2022; 38 Boye (ref20) 2021; 23 Noben (ref25) 2020; 97 ref2 Philis-Tsimikas (ref31) 2023; 25 Wei (ref44) 2019; 10 Harris (ref12) 2010; 56 van Heuckelum (ref28) 2019; 13 Seng (ref40) 2021; 21 Stewart (ref27) 2016; 10 Liu (ref35) 2023; 8 Khan (ref1) 2020; 10 Polonsky (ref9) 2004; 22 Savarese (ref33) 2023; 371 Boye (ref21) 2021; 12 ElSayed (ref5) 2023; 46 Kerr (ref14) 2022; 28 Blumer (ref11) 2017; 39 Yavuz (ref6) 2015; 9 Russell-Jones (ref10) 2018; 20 Kerr (ref13) 2020; 14 Perez-Nieves (ref15) 2018; 9 Tomaszewski (ref24) 2019; 13 ref43 Rolla (ref19) 2008; 121 Singh (ref32) 2022; 16 Klonoff (ref37) 2021; 15 Laiteerapong (ref4) 2019; 42 Flood (ref22) 2017; 33 Huang (ref36) 2021; 9 Peyrot (ref8) 2005; 28 Brod (ref17) 2012; 28 Lingvay (ref29) 2023; 330 Ahlqvist (ref41) 2018; 6 ref7 Sarbacker (ref16) 2016; 29 Davis (ref42) 2022; 45 Philis-Tsimikas (ref30) 2023; 11 Fang (ref3) 2022; 45 Rutten (ref38) 2020; 8 Pagidipati (ref39) 2023; 329 Ozdemir (ref34) 2020; 23 Garcia-Dominguez (ref26) 2016; 10 |
References_xml | – volume: 46 start-page: S140 year: 2023 ident: ref5 publication-title: Diabetes Care doi: 10.2337/dc23-S009 contributor: fullname: ElSayed – volume: 28 start-page: 811 year: 2022 ident: ref14 publication-title: Endocr Pract doi: 10.1016/j.eprac.2022.04.006 contributor: fullname: Kerr – volume: 21 start-page: 49 year: 2021 ident: ref40 publication-title: BMC Med. Res. Method. doi: 10.1186/s12874-021-01209-w contributor: fullname: Seng – volume: 20 start-page: 488 year: 2018 ident: ref10 publication-title: Diabetes Obes Metab doi: 10.1111/dom.13132 contributor: fullname: Russell-Jones – volume: 8 start-page: 56 year: 2023 ident: ref35 publication-title: BMJ Glob Health doi: 10.1136/bmjgh-2022-010942 contributor: fullname: Liu – ident: ref43 – volume: 10 start-page: 107 year: 2020 ident: ref1 publication-title: J Epidemiol Glob Health doi: 10.2991/jegh.k.191028.001 contributor: fullname: Khan – volume: 23 start-page: 844 year: 2021 ident: ref18 publication-title: Diabetes Technol. Ther. doi: 10.1089/dia.2021.0164 contributor: fullname: Robinson – volume: 10 start-page: 1385 year: 2016 ident: ref27 publication-title: Patient Prefer Adherence doi: 10.2147/ppa.S101821 contributor: fullname: Stewart – volume: 97 start-page: 515 year: 2020 ident: ref25 publication-title: Postgraduate Medi J doi: 10.1136/postgradmedj-2019-137190 contributor: fullname: Noben – volume: 45 start-page: 484 year: 2022 ident: ref42 publication-title: Diabetes Care doi: 10.2337/dc21-2396 contributor: fullname: Davis – volume: 45 start-page: 1994 year: 2022 ident: ref3 publication-title: Diabetes Care doi: 10.2337/dc22-0242 contributor: fullname: Fang – volume: 9 start-page: 1225 year: 2015 ident: ref6 publication-title: Patient Prefer Adherence doi: 10.2147/ppa.S87935 contributor: fullname: Yavuz – volume: 39 start-page: S1 year: 2017 ident: ref11 publication-title: Clin. Ther. doi: 10.1016/j.clinthera.2016.09.020 contributor: fullname: Blumer – volume: 6 start-page: 361 year: 2018 ident: ref41 publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(18)30051-2 contributor: fullname: Ahlqvist – volume: 9 start-page: 1099 year: 2018 ident: ref15 publication-title: Diabetes Ther doi: 10.1007/s13300-018-0421-5 contributor: fullname: Perez-Nieves – volume: 56 start-page: e418 year: 2010 ident: ref12 publication-title: Can Fam Physician contributor: fullname: Harris – volume: 10 start-page: 536 year: 2019 ident: ref44 publication-title: Front Endocrinol doi: 10.3389/fendo.2019.00536 contributor: fullname: Wei – volume: 13 start-page: 761 year: 2019 ident: ref24 publication-title: Patient Prefer Adherence doi: 10.2147/ppa.S194598 contributor: fullname: Tomaszewski – volume: 330 start-page: 228 year: 2023 ident: ref29 publication-title: JAMA doi: 10.1001/jama.2023.11313 contributor: fullname: Lingvay – volume: 10 start-page: 1945 year: 2016 ident: ref26 publication-title: Patient Prefer Adherence doi: 10.2147/ppa.S114619 contributor: fullname: Garcia-Dominguez – ident: ref2 – volume: 42 start-page: 416 year: 2019 ident: ref4 publication-title: Diabetes Care doi: 10.2337/dc17-1144 contributor: fullname: Laiteerapong – volume: 28 start-page: 2673 year: 2005 ident: ref8 publication-title: Diabetes Care doi: 10.2337/diacare.28.11.2673 contributor: fullname: Peyrot – volume: 15 start-page: 177 year: 2021 ident: ref37 publication-title: J Diabetes Sci Technol doi: 10.1177/1932296820973185 contributor: fullname: Klonoff – volume: 25 start-page: 331 year: 2023 ident: ref31 publication-title: Diabetes Obes Metab doi: 10.1111/dom.14871 contributor: fullname: Philis-Tsimikas – volume: 29 start-page: 166 year: 2016 ident: ref16 publication-title: Diabetes Spectr doi: 10.2337/diaspect.29.3.166 contributor: fullname: Sarbacker – volume: 22 start-page: 147 year: 2004 ident: ref9 publication-title: Clin Diabetes doi: 10.2337/diaclin.22.3.147 contributor: fullname: Polonsky – volume: 9 start-page: 782964 year: 2021 ident: ref36 publication-title: Front Public Health doi: 10.3389/fpubh.2021.782964 contributor: fullname: Huang – volume: 23 start-page: 842 year: 2020 ident: ref34 publication-title: Value Health doi: 10.1016/j.jval.2020.01.023 contributor: fullname: Ozdemir – volume: 8 start-page: e001926 year: 2020 ident: ref38 publication-title: BMJ Open Diabetes Res Care doi: 10.1136/bmjdrc-2020-001926 contributor: fullname: Rutten – volume: 14 start-page: 1107 year: 2020 ident: ref13 publication-title: J Diabetes Sci Technol doi: 10.1177/1932296820963630 contributor: fullname: Kerr – volume: 33 start-page: 261 year: 2017 ident: ref22 publication-title: Curr Med Res Opin doi: 10.1080/03007995.2016.1253553 contributor: fullname: Flood – volume: 121 start-page: S9 year: 2008 ident: ref19 publication-title: Am J Med doi: 10.1016/j.amjmed.2008.03.022 contributor: fullname: Rolla – volume: 23 start-page: 508 year: 2021 ident: ref20 publication-title: Diabetes Obes Metab doi: 10.1111/dom.14244 contributor: fullname: Boye – volume: 11 start-page: 414 year: 2023 ident: ref30 publication-title: Lancet Diabetes Endocrinol doi: 10.1016/s2213-8587(23)00093-1 contributor: fullname: Philis-Tsimikas – volume: 38 start-page: 1831 year: 2022 ident: ref23 publication-title: Curr. Med. Res. Opin. doi: 10.1080/03007995.2022.2125259 contributor: fullname: King – volume: 13 start-page: 1199 year: 2019 ident: ref28 publication-title: Patient Prefer Adherence doi: 10.2147/ppa.S204111 contributor: fullname: van Heuckelum – volume: 329 start-page: 1261 year: 2023 ident: ref39 publication-title: JAMA doi: 10.1001/jama.2023.2854 contributor: fullname: Pagidipati – volume: 28 start-page: 1933 year: 2012 ident: ref17 publication-title: Curr Med Res Opin doi: 10.1185/03007995.2012.743458 contributor: fullname: Brod – volume: 12 start-page: 2387 year: 2021 ident: ref21 publication-title: Diabetes Therapy doi: 10.1007/s13300-021-01097-9 contributor: fullname: Boye – volume: 371 start-page: 526 year: 2023 ident: ref33 publication-title: Int J Cardiol doi: 10.1016/j.ijcard.2022.09.009 contributor: fullname: Savarese – volume: 16 start-page: 102615 year: 2022 ident: ref32 publication-title: Diabetes Metab Syndr doi: 10.1016/j.dsx.2022.102615 contributor: fullname: Singh – ident: ref7 doi: 10.1136/bmj.310.6972.83 |
SSID | ssj0063621 |
Score | 2.376149 |
Snippet | The global burden of disease of type 2 diabetes (T2D) is significant, and insulin currently plays a central role in T2D management. This study sought to assess... Purpose: The global burden of disease of type 2 diabetes (T2D) is significant, and insulin currently plays a central role in T2D management. This study sought... Plain Language Summary: Type 2 diabetes (T2D) is a medical condition where the body has difficulty managing insulin, a hormone used to control glucose, or... PurposeThe global burden of disease of type 2 diabetes (T2D) is significant, and insulin currently plays a central role in T2D management. This study sought to... Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use: https://youtu.be/yPQljy98UFw Type 2 diabetes... David Kerr,1 Jigar Ramesh Rajpura,2 Tarlan Namvar3 1Center for Health Systems Research, Sutter Health, Santa Barbara, CA, USA; 2Department of US Health... |
SourceID | doaj pubmedcentral proquest gale crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 411 |
SubjectTerms | diabetes mellitus Diabetics Dosage and administration Drug therapy Insulin long-acting Medical personnel Original Research patient preference Personal preferences (Social sciences) provider preference Psychological aspects Surveys surveys and questionnaires type 2 Type 2 diabetes |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3PaxQxFA7Sg3gRa_0xtmoKBU9jm8mPyRy30tIWqgta6C28ZBKth6k42__f9ybZZQcPXoRdCJvsMMmXvHwvefnC2FEEgNSHjrb-U61E0LW3cFILAWCAFNamHd3rz-biRl3d6tutq74oJizLA-eGO04G_9ZrL4OUaDuRzzep79qTiLw9CdNP1lfotTOVbbBBsyzyaTy6h-d4uVx8_KqkmdY4tuafSab_b2O8NRvNIyW3pp7zZ-xp4Yx8kd91lz2Kw3P2-Lrsiu-xn2dFsnv4zpdZJ5XD0PNlOWWHibWc7MiRpHLgXzBdZzV9fgojPv0yB6Vz_CxIk2PktETLyU_lDS-BM-MLdnN-9u3TRV3uUKiDVmZVIw7KBgE2oafiYxNkEEq3CmsEjUrGygAefZDYmhaS8jEqL4JUHgxStU7Jl2xnuB_ia8ZDp2OU4HWSSYHsrE34Naa3IFvbtRU7Wres-5WlMhy6GASAQwBcAaBip9TqmyKkbz39gKi7grr7F-oVe0-YuXxYdDNK3aK1pkVGamXFPkwlaJwidAHKcQOsCylezUoezEri-Aqz7MN1v3CURUFpQ7x_GF3TNdZqclAr9ir3k02tyPHXyJUqZmc9aFbtec5w92OS9xZ0yYAw7Zv_0VD77EmDNCwvGh2wndXvh_gWadTKv5tGzB8ZLBqU priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3di9QwEA_nCeLL4bfVUyMc-NTz0nz2QWRP7jiF1QVd2LcwTZM7Rbrndg_0v3fSZJerCkILpUkLk5lJZjKT3xBy4AEgtK6Oof9QCuZk2Rg4KhkDUBAR1oaI7vSjOpuLDwu52CGbYpx5APt_unaxntR89f3w549fb1Hh38Q0Zib069lscvhZcIXGxw1ysxJcRFGfim04QeEszVKVFZySTb1IB_X-_Hi0NA0I_n_P09cWqnES5bVV6fQO2cvmJJ0k_t8lO767R25Nc8D8Pvl2ktG8u3M6SxCqFLqWzvIBPHzYIM32FO1XCvQTPpcJaJ8eQ49_f5_y1SlekwjX0dO4e0ujC0srmnNq-gdkfnry5d1ZmcsrlE4KtS6RRcI4BiagE9P4ynHHhNQCKYJKBGW4gwbdE6-VhiAa70XDHBcNKLTiasEfkt1u2fnHhLpaes-hkYEHAbw2JuCtVGuAa1PrghxsRtZeJhQNi95HZIBFBtjMgIIcx1HfdonQ18OL5ercZk2yQaEctbLhjnNcTNHBq0Jb6yOPjlxgqi3Ii8gzm86RbhXYTrRRGo1VwwvyaugRhQpZ5yCfREBaIhjWqOf-qCeqnhs1v9zIhY1NMV-t88ur3lZ1ZYyMvmtBHiU52VIV9wQkmlEFMSMJGpE9bum-XgzI3yzWH2BKP_kvjU_J7QrNr7RZtE9216sr_wzNp3XzfFCN33vFF94 priority: 102 providerName: Scholars Portal |
Title | Evaluating Patient and Provider Preferences for a Once-Weekly Basal Insulin in Adults with Type 2 Diabetes |
URI | https://www.ncbi.nlm.nih.gov/pubmed/38375061 https://search.proquest.com/docview/2928854013 https://pubmed.ncbi.nlm.nih.gov/PMC10875167 https://doaj.org/article/f611ad5b3c334294952fd970e259f16d |
Volume | 18 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9swED6aDsZexn7PW5dpUNiTk8iSJfkxCSnZIJ3ZVuiejCxLbcfqlDr9_3ey7BCzt4EtjCUbS3eS7pPuPgOcWq21q0zmt_5dzKlJ41LpWUyp1kJ7hrV2R3dzLtYX_OtlenkEoo-FaZ32TXkzqf_cTuqb69a38u7WTHs_sWm-WVJPw06FnI5gJBnrMXoYfwUOyTRE4vl_8EzzfD75wZlo1zcO5p6Wov_fgfhgJhp6SR5MO2fP4GlnL5J5-K7ncGTrF_B40-2Iv4Tfq46uu74ieeBIJbquSN5F2OFFTyXbEDRQiSbf8DoOTPpkoRt8-5fgkE7wmHs-job45VniMSpJSOc007yCi7PVz-U67v6fEJuUi12MMuDKUK0copTSJoYZylPJsUY64U4oZnSJ-MNKIbXjpbW8pIbxUgs00zLOXsNxva3tWyAmS61lukwdc1yzTCmHpxCV0kyqTEZw2rdscRdoMgqEF14ABQqg6AQQwcK3-r6I57Zub2zvr4pOwoUTqChVWjLDGM6WiOASV2VyZhGpOSqqCD56mRUhUHTfQ4u5VEKiNapYBJ_bEr6PouiM7kINsC6e7WpQ8mRQEvuWGWR_6vWi8FneIa2224emSLJEqdSD0wjeBD3Z18qD_hTtpAjUQIMG1R7moKa31N69Zr_7_0ffw5MEDa-wTHQCx7v7B_sBDaddOYbR7NcaU7WkY3i0WJ3n38ftIgSmG67GbT_6C2fEH4M |
link.rule.ids | 230,315,733,786,790,870,891,2115,24346,27955,27956,33300,33778,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgEX3o9AoUaqxCm7Tew4znFbtdpCt0SiFb1ZtmOXtjRbNbsXfj3jOFlt4ARSIlmxE8WeGc-MPfMZYMcqpVxlCr_172KWmCzWQu3GSaIUVx5hrd3RnZ3w6Rn7fJ6dbwDvc2HaoH2jL0f1z5tRffmjja28vTHjPk5sXM72Ew_DnvB8fA_uo8CmWe-lhxmY46SchFw8fwrPuCwno2-M8naFY037tCD9f0_Fa7poGCe5pngOn8D3_pdDvMn1aLnQI_PrDzTHf-_TU3jc2aJkEuqfwYatn8ODWbfb_gKuDjoo8PqClAF_lai6ImWXvYeFHqa2IWj8EkW-YjkOKP1kTzX49aMQ7E7wmnisj4b4pV_i_V-Ski4gp3kJZ4cHp_vTuDubITYZ44sY6cuESZRw6AFpmxpqEpblDMdKpcxxQY3S6NvYnOfKMW0t04mhTCuOJmDB6CvYrOe1fQPEFJm1VOnMUccULYRweHNeCUVzUeQR7PQ0k7cBgkOi6-JJK5G0siNtBHuenqsmHje7fTC_u5DdSEvHkQmrTFNDKWpi9A5TVxX5rkUv0CW8imDbc4MMSagr6ZeTXPAcLV1BI_jUtvDyj0xhVJfGgH3xSFqDlluDlii3ZlD9sec46at8sFtt58tGpkUqROYd3wheBw5c9covKGRog0UgBrw56PawBjmuhQ3vOezt_7-6DQ-np7NjeXx08uUdPErRwAvLUVuwubhb2vdooC30h1YafwMV_jyF |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSBUX3o9AoUaqxClJEzuOc9yWrlpgSySoVImDZTt2aUuzq2b3wq9nHDurDdwqJVIUT6LYMx7P2J-_ILRnpJS20ZVb-rcxzXQRKy734yyTkknHsNav6M5O2fEZ_XxenAdUZRdgla1Wl0n7-yZpL3_12MrFjU4HnFhazw4zR8OesTJdNDa9jx5Ap83LIVP3XpiBY878fjz3J560rifJd0pYP8uxMQL1RP3_u-ON8WiMldwYfKaP0c_hsz3m5DpZLVWi__zD6Hi3ej1Bj0JMiide5im6Z9pnaHsWVt2fo6ujQAneXuDa87Bi2Ta4Drv44GKgq-0wBMFY4m9wHXu2fnwgO3j7iQe9YzgmjvOjw24KGLs8GOc4AHO6F-hsevTj8DgO_2iIdUHZMgY9U64zyS1kQsrkmuiMFiWF9pI5tYwTLRXkOKZkpbRUGUNVpglVkkEoWFHyEm2189a8RlhXhTFEqsISSyWpOLdwMtZwSUpelRHaG_QmFp6KQ0AK49QrQL0iqDdCB06naxHHn93fmN9eiNDawjIwxqZQRBMCIzJkibltqnLfQDZoM9ZEaNdZhPCbUddeQExKzkqIeDmJ0MdewvkBMAwtw3YGqItj1BpJ7owkof_qUfGHweqEK3Kgt9bMV53Iq5zzwiXAEXrlrXBdKzexUEAsFiE-ss9RtcclYHU9ffhgZW_u_ugu2q4_TcXXk9Mvb9HDHOI8Pyu1g7aWtyvzDuK0pXrfd8i_6xU_BQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluating+Patient+and+Provider+Preferences+for+a+Once-Weekly+Basal+Insulin+in+Adults+with+Type+2+Diabetes&rft.jtitle=Patient+preference+and+adherence&rft.au=Namvar%2C+Tarlan&rft.au=Kerr%2C+David&rft.au=Ramesh+Rajpura%2C+Jigar&rft.date=2024-01-01&rft.pub=Dove+Medical+Press+Limited&rft.issn=1177-889X&rft.eissn=1177-889X&rft.volume=18&rft.spage=411&rft_id=info:doi/10.2147%2FPPA.S436540&rft.externalDBID=n%2Fa&rft.externalDocID=A786732683 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1177-889X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1177-889X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1177-889X&client=summon |